For a patient with obesity in the United States, the path to a GLP-1 prescription has historically run through a primary care visit, a specialist referral, a prior authorization fight, and a pharmacy that may or may not have the drug in stock. Ro, the New York direct-to-patient telehealth company founded in 2017, is trying to compress that journey into a phone screen and a monthly fee. As of March 2026, the company says patients can save up to $1,200 per year on the Wegovy pen or $600 per year on the Wegovy pill through a collaboration with Novo Nordisk, with prepaid 3, 6, and 12 month plans for cash-paying patients [Ro, March 2026]. That is the kind of pricing mechanic that, if it holds, reshapes how a chronic disease gets treated outside the four walls of a clinic.
The standard of care today for adults with obesity (BMI 30+, or 27+ with a comorbidity such as type 2 diabetes or hypertension) is a stepwise approach: lifestyle counseling first, then pharmacotherapy, then bariatric surgery for the most severe cases. GLP-1 receptor agonists including semaglutide (Wegovy, approved by the FDA in 2021) and tirzepatide (Zepbound, approved 2023) have moved quickly into first-line pharmacotherapy because of trial-grade weight loss in the 15 to 22 percent range. Access, however, remains the binding constraint. Insurance coverage for obesity indications is uneven, supply has been intermittent, and many primary care physicians still lack the time or training to manage titration and side effects. That gap is the wedge Ro is selling into.
The bet
Ro's pitch is that a single membership can stitch together the prescriber visit, the labs, the medication, and the coaching that GLP-1 therapy actually requires. Ro Body, the company's weight loss program, is priced at $39 for the first month and as low as $74 per month on an annual prepay [Ro]. The program bundles GLP-1 medications, lab testing, and one-to-one coaching with provider care [PR Newswire]. Ro also offers Eli Lilly's Foundayo through the same channel [PR Newswire], which gives the company a foothold in both major branded GLP-1 franchises rather than a dependence on one manufacturer.
Weight loss is now the commercial center of gravity. Ro generated roughly $370 million in GLP-1 revenue in 2024 according to Sacra [Sacra], a figure that, if accurate, would make obesity care the dominant line in a business that began with erectile dysfunction under the Roman brand. The company has continued to broaden the ED catalog with compounded products including Daily Rise gummies and Sparks [Wikipedia], and it operates nationwide telehealth, labs, and pharmacy services [Built In NYC]. The vertical integration is the point: a patient who starts on semaglutide can get bloodwork, dose adjustments, and refills without leaving the app.
Why it could be big
The investor syndicate behind Ro reads like a bet that direct-to-patient care becomes a standalone channel rather than a feature of a payer or hospital system. General Catalyst led a $500 million Series D in March 2021 [Ro, March 2021], following a $200 million Series C in July 2020 [Ro, July 2020]. ShawSpring led a further $150 million round in February 2022 [Tracxn]. Total disclosed funding sits near $1.03 billion, with Altimeter, Baupost, Dragoneer, FirstMark, Initialized, and TQ Ventures also on the cap table.
Series C Jul 2020 | 200 | $M
Series D Mar 2021 | 500 | $M
Series D Feb 2022 | 150 | $M
GLP-1 revenue 2024 | 370 | $M
The macro tailwind is the GLP-1 category itself, which sell-side analysts have repeatedly modeled as one of the largest pharmaceutical opportunities of the decade. If even a modest share of treatment-eligible adults migrates to telehealth-mediated care, a vertically integrated operator with its own pharmacy and a direct relationship with manufacturers has structural advantages over a referral-based clinic model. Ro's published outcomes data claims average weight loss of 11 to 20 percent at one year, compared with roughly 2 to 3 percent on diet and exercise alone [Ro], a range broadly consistent with the pivotal STEP and SURMOUNT trials, though those comparisons are company-reported rather than independently peer-reviewed in this format [Ro].
The team and traction
Ro was co-founded by Zachariah Reitano, Rob Schutz, and Saman Rahmanian, with Reitano serving as chief executive [Initialized Capital]. Margo Georgiadis, formerly chief executive of Ancestry.com, joined the board of directors [Wikipedia], adding consumer subscription experience to a company whose economics increasingly resemble a subscription business. Active hiring, including a Staff Software Engineer for Identity and Privacy and a Manager for Training and Quality Assurance in Customer Experience [Ro], suggests continued investment in the compliance and service layers that a regulated DTC pharmacy needs to scale.
The honest counterfactual
The most credible bear case is competitive and regulatory. Hims and Hers has built a public-market business on a similar DTC playbook, and Curology, Musely, and Nurx all compete for overlapping patient populations. On the regulatory side, FDA scrutiny of compounded GLP-1s has tightened as the official shortage status of semaglutide and tirzepatide has shifted, which raises questions for any telehealth operator that has relied on compounded versions to bridge supply or price gaps. Ro's answer, visible in the Wegovy savings collaboration with Novo Nordisk [Ro, March 2026] and the inclusion of Lilly's Foundayo [PR Newswire], is to move the business toward branded, on-label dispensing with manufacturer-supported pricing rather than away from it. That is the more durable position if compounding pathways narrow further.
What to watch
Over the next twelve months, the questions worth tracking are concrete. Does the Novo Nordisk savings program convert into measurable membership growth, and does Ro publish 68-week real-world outcomes that hold up to peer review rather than press release [Ro]? Does the company expand the manufacturer collaboration model to additional branded therapies, including cardiometabolic indications where GLP-1s are gaining label expansions? And does Ro raise again, or begin signaling a path to public markets, given the scale its 2024 revenue figure implies?
For patients with obesity, the clinically meaningful question is not which app prescribes the drug. It is whether the care wrapped around the prescription, the labs, the titration, the coaching, the side-effect management, is good enough to produce trial-like outcomes outside a trial. Ro is making a billion-dollar bet that it can be. The disease state deserves the attention. The evidence deserves the same.
Pulse Raman, Health and Bio Correspondent